SI
BIO icon

Stephens Inc’s Bio-Rad Laboratories Class A BIO Stock Holding History

Stephens Inc’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-421
Closed -$202K – 1237
2023
Q1 		$202K Buy
+421
New +$197K ﹤0.01% 1033
2022
Q3 		– Sell
-476
Closed -$236K – 1209
2022
Q2 		$236K Sell
476
-90
-16% -$46.9K ﹤0.01% 1010
2022
Q1 		$319K Buy
566
+80
+16% +$48.2K 0.01% 991
2021
Q4 		$367K Sell
486
-1
-0.2% -$748 0.01% 967
2021
Q3 		$363K Sell
487
-35
-7% -$26.2K 0.01% 972
2021
Q2 		$336K Sell
522
-5
-0.9% -$3.04K 0.01% 996
2021
Q1 		$301K Buy
527
+12
+2% +$7.11K ﹤0.01% 1002
2020
Q4 		$300K Sell
515
-54
-9% -$30.8K 0.01% 918
2020
Q3 		$293K Sell
569
-3
-0.5% -$1.52K 0.01% 877
2020
Q2 		$258K Sell
572
-36
-6% -$15.9K 0.01% 888
2020
Q1 		$213K Sell
608
-20
-3% -$7.35K 0.01% 872
2019
Q4 		$232K Sell
628
-26
-4% -$9.17K ﹤0.01% 966
2019
Q3 		$218K Buy
+654
New +$213K ﹤0.01% 1023

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Stephens Inc's BIO Position: Q2 2023 in Review

Stephens Inc sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 421 shares — an estimated $202K sold.

Stephens Inc first reported a position in BIO in Q3 2019 and held it in 13 quarters. The position peaked at $367K in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Stephens Inc reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Stephens Inc sold 421 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $202K.
  • Stephens Inc first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 13 quarters.
  • Stephens Inc's Bio-Rad Laboratories Class A position peaked at $367K in Q4 2021.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Stephens Inc's 13F filing for Q2 2023, filed 14 Aug 2023.